Drugs for Prolymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 248)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Cefepime |
Approved, Investigational |
Phase 3 |
|
88040-23-7 |
5479537 |
Synonyms:
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
1-(((6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methylpyrrolidinium hydroxide, inner salt, 7(sup 2)-(Z)-(O-methyloxime)
7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(1-methylpyrrolidinium-1-yl)methyl]-3,4-didehydrocepham-4-carboxylate
88040-23-7
AC1NUIFH
Axepim
Axépim
BMY 28142
BMY-28142
Bristol-myers brand OF cefepime dihydrochloride
Bristol-myers squibb brand OF cefepime dihydrochloride
C08111
C19H24N6O5S2
Cefepim
Cefepima
Cefepima [Spanish]
cefepime
Cefepime
Cefepime (USAN/INN)
|
Cefepime [USAN:INN]
Cefepime hydrochloride
Cefepimum
Cefepimum [Latin]
Cepimax
Cepimex
CFPM
CHEBI:478164
CHEMBL186
CID5479537
D02376
DB01413
Elan brand OF cefepime dihydrochloride
HMS2089M18
LS-178033
Maxcef
Maxipime
Quadrocef
UNII-807PW4VQE3
ZINC03871924
|
|
2 |
|
Levofloxacin |
Approved, Investigational |
Phase 3 |
|
100986-85-4 |
149096 |
Synonyms:
(−
(-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate
(-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyridol[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate
(-)-Ofloxacin
(3S)-(-)-9-fluoro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylate
(3S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid
(3S)-(-)-9-fluoro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid
(3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
(R)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(R)-isomer
(S)-(-)-9-fluoro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylate
(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
(S)-(-)-9-fluoro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
(S)-(-)-Ofloxacin
(S)-9-fluoro-2,3-dihydro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylate
(S)-9-fluoro-2,3-dihydro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(S)-Ofloxacin
)-Ofloxacin
100986-85-4
100986-86-5
28266_FLUKA
28266_SIGMA
AC1L3YF8
AC-7593
Aeroquin
Ambap100986-85-4
Anhydrous, levofloxacin
BRD-K09471561-001-06-7
BSPBio_002689
C07660
C18H20FN3O4
C18H20FN3O4.H2O
CCRIS 4073
CCRIS 4074
CHEMBL33
CID149096
CPD000466387
Cravit
Cravit (TN)
Cravit Ophthalmic
D08120
DB01137
d-Levofloxacin
DR 3354
DR3355
DR-3355
DR-3355: L-isomer of ofloxacin
Elequine
Floxacin
Floxel
Floxin
HMS1922J07
HMS2051G04
HMS2090O10
HMS2093E18
HR 355
HR-355
Iquix
KBio2_002199
|
KBio2_004767
KBio2_007335
KBio3_001909
KBioGR_001605
KBioSS_002199
L0193
Leroxacin
Lesacin
Levaquin
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER
Levofloxacin
LEVOFLOXACIN
Levofloxacin (INN)
Levofloxacin [USAN:INN:JAN]
Levofloxacin anhydrous
Levofloxacin hydrate
Levofloxacin tablet, suspension or intravenous
Levofloxacine
Levofloxacine [INN-French]
Levofloxacino
Levofloxacino [INN-Spanish]
Levofloxacinum
Levofloxacinum [INN-Latin]
Levokacin
Levox
Levoxacin
LFX
L-Ofloxacin
LS-133260
LS-171761
LVX
MLS000759524
MLS001165709
MLS001423977
MolPort-002-885-835
Mosardal
MP-376
NCGC00178529-01
Nofaxin
Ofloxacin
Ofloxacin S-(-)-form
Ofloxacin, (S)-isomer
Oftaquix
Quixin
Reskuin
R-Ofloxacin
RWJ 25213-097
RWJ-25213
S-(-)-Ofloxacin
S1940_Selleck
SAM001246758
SMR000466387
SPBio_001891
Spectrum_001719
SPECTRUM1504260
Spectrum2_001676
Spectrum3_000995
Spectrum4_001123
Spectrum5_001438
Tavanic
Volequin
|
|
3 |
|
Ofloxacin |
Approved |
Phase 3 |
|
82419-36-1 |
4583 |
Synonyms:
( -)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure
(+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperaz inyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7- -oxo-7H-pyrido(1,2,3-de)- -1,4-benzoxazine-6-carboxylic acid
(+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid
(+/-)-Floxin
118120-51-7 (hydrochloride)
33703_FLUKA
33703_RIEDEL
82419-36-1
83380-47-6
85344-55-4
8-fluoro-3-Methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylate
8-fluoro-3-Methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid
8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
AB00513820
AC1L1IHM
AC-7616
Akilen
AKOS001033517
Baccidal
Bactocin
BB_SC-1252
BPBio1_000345
BRD-A24228527-001-05-9
BRN 3657947
BSPBio_000313
BSPBio_003117
C07321
C18H20FN3O4
CCRIS 5233
CHEBI:7731
CHEMBL4
CID4583
CPD000058192
D00453
Danoflox
DB01165
DEXTROFLOXACINE
DivK1c_000721
DL 8280
DL-8280
DL-8280, HOE-280, Exocin, Flobacin, Floxin, Floxil, Monoflocet, Ofloxacin
Effexin
EU-0100904
Exocin
Exocine
Flobacin
Flodemex
Flotavid
Flovid
Floxal
Floxil
Floxin
Floxin (TN)
FLOXIN IN DEXTROSE 5%
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER
Floxin otic
Floxstat
Fugacin
HMS1568P15
HMS1921H12
HMS2090F07
HMS2092B10
HMS502E03
Hoe 280
HOE 280
Hoe-280
I06-0112
I06-0380
IDI1_000721
Inoflox
KBio1_000721
KBio2_001666
KBio2_004234
KBio2_006802
KBio3_002617
KBioGR_000667
KBioSS_001666
Kinflocin
Kinoxacin
Liflox
Lopac0_000904
Loxinter
LS-133259
Marfloxacin
Medofloxine
Mergexin
MLS000028749
MLS001074203
MolPort-000-422-241
MolPort-000-873-068
NCGC00015772-02
NCGC00015772-10
|
NCGC00094219-01
NCGC00094219-02
NCGC00094219-03
NCGC00094219-04
NCGC00094219-05
NCGC00094219-06
NCGC00178284-01
NCGC00178284-02
NINDS_000721
Novecin
NSC727071
Nufafloqo
O 8757
O8757_SIGMA
Obide
Occidal
Ocuflox
Ofcin
Oflin
Oflocee
Oflocet
Oflocin
Oflodal
Oflodex
Oflodura
Oflox
O-Flox
ofloxacin
Ofloxacin
Ofloxacin (JP15/USP/INN)
Ofloxacin [USAN:BAN:INN:JAN]
Ofloxacin hydrochloride
Ofloxacin Otic
Ofloxacin, (S)-Isomer
Ofloxacina
Ofloxacina [DCIT]
Ofloxacine
Ofloxacine [French]
Ofloxacino
Ofloxacino [Spanish]
Ofloxacinum
Ofloxacinum [Latin]
Ofloxin
OFLX
Ofus
OFX
Onexacin
Operan
Oprea1_242882
ORF 18489
ORF-28489
Orocin
Otonil
Oxaldin
Pharflox
Praxin
Prestwick0_000237
Prestwick1_000237
Prestwick2_000237
Prestwick3_000237
PT 01
Puiritol
Qinolon
Qipro
Quinolon
Quotavil
Rilox
Ru-43280
S1463_Selleck
SAM002264629
Sinflo
SMR000058192
SPBio_001387
SPBio_002234
Spectrum_001186
SPECTRUM1502044
Spectrum2_001464
Spectrum3_001499
Spectrum4_000324
Spectrum5_001063
STK256723
Tabrin
Taravid
Tariflox
Tarivid
Telbit
Tructum
UNII-A4P49JAZ9H
Uro Tarivid
Viotisone
Visiren
WP-0405
XED
Zanocin
|
|
4 |
|
Ketamine |
Approved, Vet_approved |
Phase 3 |
|
6740-88-1 |
3821 |
Synonyms:
(-)-Ketamine
(+-)-Ketamine
(+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-Ketamine
(±)-ketamine
(S)-(-)-Ketamine
(S)-Ketamine
100477-72-3
2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(2-chloro-Phenyl)-2-methylamino-cyclohexanone
2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone
2-(methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(methylamino)-2-(2-Chlorophenyl)cyclohexanone
2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone
2-(O-Chlorophenyl)-2-(methylamino)-cyclohexanone
33643-45-7
6740-88-1
79499-51-7
AC1L1GSH
AC1Q40UR
AKOS001053247
BRN 2216965
C07525
C13H16ClNO
Calipsol
Calypsol
Cetamina
Cetamina [INN-Spanish]
CHEBI:138833
CHEBI:6121
CHEMBL742
CI 581 base
CI-581
CID3821
CLSTA 20
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)- (9CI)
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)- (9CI)
Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8CI)
D08098
DB01221
DEA No. 7285
DivK1c_000217
|
dl-Ketamine
DL-ketamine
DL-Ketamine
EINECS 229-804-1
Esketamine
Green
IDI1_000217
Kalipsol
KBio1_000217
Ketaject
Ketalar
Ketalar base
Ketamina
ketamine
Ketamine
Kétamine
Ketamine (INN)
Ketamine [INN:BAN]
Ketamine base
Ketamine Base
Ketamine HCL
KETAMINE HCL
Ketamine hydrochloride
Ketaminum
Ketaminum [INN-Latin]
Ketanest
Ketaset
Ketoject
Ketolar
l-Ketamine
L-Ketamine
LS-57301
MLS001331674
MolPort-001-838-070
NCGC00159480-02
NCGC00159480-03
NINDS_000217
NMDA
NSC 70151
NSC70151
SMR000238141
Special K
Special K [street name]
T385
Tekam
Tekam (TN)
UNII-690G0D6V8H
|
|
5 |
|
Clotrimazole |
Approved, Vet_approved |
Phase 3 |
|
23593-75-1 |
2812 |
Synonyms:
(Chlorotrityl)imidazole
1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole
1-(a-(2-Chlorophenyl)benzhydryl)imidazole
1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole
1-(O-chloro-a,a-Diphenylbenzyl)imidazole
1-(O-chloro-alpha,alpha-Diphenylbenzyl)imidazole
1-(o-Chlorotrityl)imidazole
1-(O-Chlorotrityl)imidazole
1-(o-Chloro-α,α-diphenylbenzyl)imidazole
1-(O-chloro-α,α-diphenylbenzyl)imidazole
1-(α-(2-chlorophenyl)benzhydryl)imidazole
1-(α-(2-Chlorophenyl)benzhydryl)imidazole
117829-71-7
23593-75-1
33894_FLUKA
33894_RIEDEL
3ACDFDF8-38E3-4368-85D0-BDF8AE1E6591
AB00051951
AC1L1EIW
AC-279
B 5097
BAY 5097
Bay b 5097
BAY b 5097
Bay b 9057
BAY b5097
BAY-5097
Bay-B 5097
BAYb 5097
Bayer brand 1 OF clotrimazole
Bayer Brand 1 of Clotrimazole
Bayer brand 2 OF clotrimazole
Bayer Brand 2 of Clotrimazole
BIDD:GT0450
BIDD:PXR0036
Bio-0442
BPBio1_000126
BRN 0622318
BSPBio_000114
BSPBio_002057
C 6019
C06922
C22H17ClN2
C6019_SIGMA
Canesten
Canesten 1-day cream combi-pak
Canesten 1-Day Cream Combi-Pak
Canesten 1-day therapy
Canesten 1-Day Therapy
Canesten 3-day therapy
Canesten 3-Day Therapy
Canesten 6-day therapy
Canesten 6-Day Therapy
Canesten combi-pak 1-day therapy
Canesten Combi-Pak 1-Day Therapy
Canesten combi-pak 3-day therapy
Canesten Combi-Pak 3-Day Therapy
Canesten cream
Canesten Cream
Canesten solution
Canesten Solution
Canestene
Canestine
Canifug
CAS-23593-75-1
CCRIS 6245
CHEBI:3764
CHEMBL104
Chlotrimazole
CID2812
Cimitidine
Clomatin
Clotrimaderm
Clotrimaderm cream
Clotrimazol
Clotrimazol [INN-Spanish]
clotrimazole
Clotrimazole
Clotrimazole (JP15/USP/INN)
Clotrimazole [USAN:INN:BAN:JAN]
Clotrimazole schering brand
Clotrimazole Schering Brand
Clotrimazolum
Clotrimazolum [INN-Latin]
clotrimeizol
CPD000058306
CPD-8926
Cutistad
D00282
D003022
DB00257
Desamix F
DivK1c_000665
DRG-0072
EINECS 245-764-8
Empecid
Esparol
EU-0100315
FB 5097
FB b 5097
Fem care
Fem Care
FemCare
Gino-Lotremine
Gyne lotrimin
Gyne-lotrimin
Gyne-Lotrimin
Gyne-lotrimin 3
Gyne-Lotrimin 3
Gyne-lotrimin 3 combination pack
Gyne-Lotrimin 3 Combination Pack
Gyne-lotrimin combination pack
Gyne-Lotrimin Combination Pack
Gyne-lotrimin3
Gyne-lotrimin3 combination pack
Gynix
HMS1568F16
HMS1920O21
HMS2051E11
HMS2091G10
HMS502B07
HSDB 3266
I01-3474
IDI1_000665
|
Kanesten
KBio1_000665
KBio2_001823
KBio2_004391
KBio2_006959
KBio3_001277
KBioGR_000850
KBioSS_001823
Klotrimazole
Lopac0_000315
Lopac-C-6019
Lotrimax
Lotrimin
Lotrimin (TN)
Lotrimin af
Lotrimin Af
Lotrimin af cream
Lotrimin AF Cream
Lotrimin af jock-itch cream
Lotrimin AF Jock-Itch Cream
Lotrimin af lotion
Lotrimin AF Lotion
Lotrimin af solution
Lotrimin AF Solution
Lotrimin cream
Lotrimin Cream
Lotrimin lotion
Lotrimin Lotion
Lotrimin solution
Lotrimin Solution
Lotrisone
LS-78271
MLS000028502
MLS000758243
MLS001423972
MolPort-002-557-756
mono-Baycuten
Monobaycuten
Mono-baycuten
Mycelax
Mycelex
Mycelex (TN)
Mycelex 7
Mycelex cream
Mycelex Cream
Mycelex g
Mycelex G
Mycelex otc
Mycelex OTC
Mycelex solution
Mycelex Solution
Mycelex troches
Mycelex Troches
Mycelex twin pack
Mycelex Twin Pack
Mycelex: mycosporinrimazole
Mycelex: MycosporinRimazole
Mycelex-7
Mycelex-7 combination pack
Mycelex-7 Combination Pack
Mycelex-g
Mycelex-G
myclo Cream
Myclo Cream
myclo Solution
Myclo Solution
myclo Spray solution
Myclo Spray Solution
myclo-Gyne
Myclo-Gyne
Mycofug
Mycosporin
Mykosporin
Nalbix
NCGC00015251-01
NCGC00015251-02
NCGC00015251-03
NCGC00015251-09
NCGC00093761-01
NCGC00093761-02
NCGC00093761-03
NCGC00093761-04
NCGC00093761-05
NCGC00093761-06
nchembio.65-comp9
nchembio790-comp30
NCIMech_000609
neo-Zol cream
Neo-Zol Cream
NINDS_000665
NSC 257473
NSC257473
Otomax
Pan-Fungex
Pedisafe
Prestwick_120
Prestwick0_000267
Prestwick1_000267
Prestwick2_000267
Prestwick3_000267
QTL1_000024
Rimazole
S1606_Selleck
SAM001247056
Schering brand OF clotrimazole
Schering Brand of Clotrimazole
SMR000058306
SPBio_000176
SPBio_002333
Spectrum_001343
SPECTRUM1500200
Spectrum2_000128
Spectrum3_000359
Spectrum4_000295
Spectrum5_000781
Stiemazol
STK700023
Tibatin
Trimysten
Trivagizole 3
UNII-G07GZ97H65
Veltrim
ZINC03807804
|
|
6 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 3 |
|
22916-47-8 |
4189 |
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
Aflorix(nitrate)
AKOS001574474
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
Brentan
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
Conofite(nitrate)
CPD-4501
D00416
Dactarin
Daktarin IV
DB01110
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Esteve brand OF miconazole
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
Lotrimin AF(nitrate)
LS-78378
MCZ
Micantin (nitrate)
Miconasil nitrate
Miconasil Nitrate
Miconazol
|
Miconazol [INN-Spanish]
miconazole
Miconazole
Miconazole (JP15/USP/INN)
Miconazole [USAN:BAN:INN:JAN]
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MJR 1762
MLS002222203
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
Nitrate, miconasil
Nitrate, miconazole
Novo-Miconazole Vaginal Ovules
NSC 170986
NSC169434
NSC170986
Oprea1_091955
Prestwick_335
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
Spectrum_000965
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
STK834405
STOCK1S-93556
UNII-7NNO0D7S5M
Vusion
Zimycan
|
|
7 |
|
Busulfan |
Approved, Investigational |
Phase 2, Phase 3 |
|
55-98-1 |
2478 |
Synonyms:
1, {4-Bis[methanesulfonoxy]butane}
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis(methanesulphonoxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Butanediol dimethanesulfonic acid
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethanesulphonic acid
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonoxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
acid, tetramethylene ester
AI3-25012
AKOS003614975
alkylating agent: crosslinks guanine residues
Ambap55-98-1
AN 33501
B1022
B2635_FLUKA
B2635_SIGMA
Bisulfex
Bisulphex
BRN 1791786
BSPBio_001920
Busilvex
busulfan
Busulfan
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Busulfan (JP15/USP/INN)
Busulfan [INN:JAN]
Busulfan glaxosmithkline brand
Busulfan GlaxoSmithKline Brand
Busulfan orphan brand
Busulfan Orphan Brand
Busulfan wellcome
Busulfan Wellcome
Busulfan wellcome brand
Busulfan Wellcome Brand
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Busulphano
Busulphanum
butane-1,4-diyl dimethanesulfonate
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
Citosulfan
CPD000058613
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
glaxo Wellcome brand OF busulfan
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline brand OF busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
|
GT 2041
GT 41
HMS1920I07
HMS2091O09
HMS502K09
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
Leucosulfan
Leucosulphan
LS-1358
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MLS001076666
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myléran
MYLERAN (TN)
Myleran tablets
Myleran Tablets
Myleran, Busulfex, Busulfan
Mylerlan
n-Butane-1,3-di(methylsulfonate)
N-Butane-1,3-di(methylsulfonate)
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI60_041640
NCI-C01592
NCIMech_000192
NINDS_000847
NSC 750
NSC750
NSC-750
NSC-750sulphabutin
Orphan brand OF busulfan
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
Spectrum_000092
SPECTRUM1500152
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
ST50825921
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene {bis[methanesulfonate]}
Tetramethylene bis(methanesulfonate)
Tetramethylene bis(methanesulfonic acid)
Tetramethylene bis(methanesulphonate)
Tetramethylene bis(methanesulphonic acid)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene Dimethane Sulfonate
Tetramethylenester kyseliny methansulfonove
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
Wellcome brand OF busulfan
Wellcome Brand of Busulfan
Wellcome, busulfan
Wellcome, Busulfan
WLN: WS1&O4OSW1
X 149
|
|
8 |
|
Etoposide |
Approved |
Phase 2, Phase 3 |
|
33419-42-0 |
36462 |
Synonyms:
(−)-etoposide
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-b-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-β-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4-Demethylepipodophyllotoxin b-D-ethylideneglucoside
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4-demethylepipodophyllotoxin β-D-ethylideneglucoside
4-Demethylepipodophyllotoxin β-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-b-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-β-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
alpha-D-Glucopyranosyl isomer etoposide
Ambap33419-42-0
Baxter brand OF etoposide
Baxter oncology brand OF etoposide
Bio1_000489
Bio1_000978
Bio1_001467
BPBio1_000673
BRD-K37798499-001-02-5
Bristol myers brand OF etoposide
Bristol myers squibb brand OF etoposide
Bristol-myers brand OF etoposide
Bristol-myers squibb brand OF etoposide
BSPBio_000611
C01576
CCRIS 2392
Celltop
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl epipodophyllotoxin ethylidine glucoside
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
Eposin, Vepesid, VP-16, Toposar, Etoposide
eto GRY
eto-GRY
Etomedac
ETOP
Etopol
Etopophos
Etopophos (phosphate salt)
Etopos
|
etoposide
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposide pierre fabre
Etoposide teva
Etoposide, (5a alpha)-isomer
Etoposide, (5a alpha,9 alpha)-isomer
Etoposide, (5S)-isomer
Etoposide, alpha D glucopyranosyl isomer
Etoposide, alpha-D-glucopyranosyl isomer
Etoposido
Etoposido [INN-Spanish]
etoposido Ferrer farma
Etoposidum
Etoposidum [INN-Latin]
Etosid
Exitop
Ferrer brand OF etoposide
Gry brand OF etoposide
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
Lastet
Lemery brand OF etoposide
LS-1214
Medac brand OF etoposide
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
nchembio.573-comp8
nchembio873-comp2
NK 171
Novartis brand OF etoposide
NSC 141540
NSC141540
NSC-141540
Onkoposid
Onkoworks brand OF etoposide
Pharmachemie brand OF etoposide
Pierre fabre brand OF etoposide
Prasfarma brand OF etoposide
Prestwick_211
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Riboposid
Ribosepharm brand OF etoposide
S1225_Selleck
SAM001246880
Sanfer brand OF etoposide
SMR000112002
SPBio_002532
ST056353
Tedec meiji brand OF etoposide
Teva brand OF etoposide
Toposar
trans-Etoposide
UNII-6PLQ3CP4P3
Vepesid
VePesid
VePESID (TN)
Vepesid J
Vepeside
Vépéside sandoz
Vépéside-sandoz
VP 16
VP 16 (pharmaceutical)
VP 16213
VP 16-213
VP-16
VP-16-213
ZINC03830818
ZINC03938684
Zuyeyidal
|
|
9 |
|
Melphalan |
Approved |
Phase 2, Phase 3 |
|
148-82-3 |
460612 4053 |
Synonyms:
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
148-82-3
3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3025 c.b
3025 C.B.
3223-07-2
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-(Bis(2-chloroethyl)amino)phenylalanine
4-[Bis(2-chloroethyl)amino]-L-phenylalanine
4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
4-14-00-01689 (Beilstein Handbook Reference)
AC1LA2OE
Alanine Nitrogen Mustard
Alkeran
ALKERAN (TN)
AmbotzHAA1563
At-290
AY3360000
BIDD:GT0044
BRD-K87827419-001-02-8
BRN 2816456
BSPBio_002407
C13H18Cl2N2O2
CB 3025
CB-3025
CCRIS 374
CHEBI:165415
CHEBI:28876
CHEMBL852
CID460612
D00369
DivK1c_000653
EINECS 205-726-3
HMS2090B09
HMS2091B16
HMS502A15
HSDB 3234
IDI1_000653
KBio1_000653
KBio2_000877
KBio2_003445
KBio2_006013
KBio3_001627
KBioGR_001284
KBioSS_000877
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine
Levofalan
Levofolan
Levopholan
L-PAM
L-Phenylalanine mustard
LS-15868
LS-865
L-Sarcolysin
L-Sarcolysine
L-Sarkolysin
M2011_SIGMA
Medphalan
|
Melfalan
Melfalano
Melfalano [INN-Spanish]
melphalan
Melphalan
Melphalan (JP15/USP/INN)
MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))
Melphalan [USAN:INN:BAN:JAN]
Melphalanum
Melphalanum [INN-Latin]
Mephalan
Merphalan
MLS001333666
MLS002153368
MolPort-003-665-535
Mustard, phenylalanine
NCGC00090757-01
NCGC00090757-02
NCGC00090757-03
NCI-C04853
NINDS_000653
NIOSH/AY3360000
NSC 241286
NSC 8806
NSC241286
NSC8806
NSC-8806
P-Bis(b-chloroethyl)aminophenylalanine
p-Bis(beta-chloroethyl)aminophenylalanine
P-Bis(beta-chloroethyl)aminophenylalanine
P-Bis(β-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
P-Di-(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
phenylalanine nitrogen mu stard
Phenylalanine nitrogen mustard
p-L-Sarcolysin
P-L-Sarcolysin
p-L-sarcolysine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
P-N,N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-di(chloroethyl)aminophenylala nine
p-N-Di(chloroethyl)aminophenylalanine
Prestwick_1006
RCRA waste no. U150
Rcra waste number U150
Sarcolysine
Sarkolysin
SK-15673
SMP2_000174
SMR000058720
SPBio_000287
Spectrum_000397
SPECTRUM1500382
Spectrum2_000074
Spectrum3_000684
Spectrum4_000882
Spectrum5_001601
TL8001065
TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)
TRANSGENIC MODEL EVALUATION (MELPHALAN)
UNII-Q41OR9510P
|
|
10 |
|
Ondansetron |
Approved |
Phase 3 |
|
99614-02-5 |
4595 |
Synonyms:
(RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one
1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one
103639-04-9 (mono-hydrochloride dihydrate)
108303-49-7
116002-70-1
99614-01-4 (mono-hydrochloride)
99614-02-5
9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
AB00373674
AC1L1IIM
AKOS000599484
Apo-ondansetron
BAS 00717177
BPBio1_001118
BRD-A19736161-001-01-8
BRD-A19736161-003-03-0
BRN 3622981
BSPBio_001016
C07325
C18H19N3O
CBDivE_008994
CHEMBL46
CID4595
CPD001307702
D00456
DB00904
DESMETHYLONDANSETRON
Dihydrate, ondansetron monohydrochloride
GR 38032
GR 38032X
GR38032F
GR-38032F
HMS2090H16
Hydrochloride, ondansetron
I06-0687
I06-1329
L000456
LS-172305
LS-51878
MolPort-001-944-253
|
Monohydrochloride dihydrate, ondansetron
Monohydrochloride, ondansetron
NCI60_022780
Novo-ondansetron
ondansetron
Ondansetron
Ondansetron (JAN/USP/INN)
ondansetron (Zofran)
Ondansetron [USAN:INN:BAN]
Ondansetron hydrochloride
Ondansetron monohydrochloride
Ondansetron monohydrochloride dihydrate
Ondansetron, (+,-)-isomer
Ondansetron, (+,-)-Isomer
Ondansetron, (R)-isomer
Ondansetron, (S)-isomer
Oprea1_435466
Oprea1_852372
PHL-ondansetron
PMS-ondansetron
Prestwick0_001058
Prestwick1_001058
Prestwick2_001058
Prestwick3_001058
Ratio-ondansetron
SAM002589958
Sandoz ondansetron
SN-307
SPBio_002938
STK370548
STOCK4S-10990
TimTec1_001750
TL8006071
UNII-4AF302ESOS
Zofran
ZOFRAN IN PLASTIC CONTAINER
Zofran odt
Zofran ODT
Zofran ODT (TN)
Zophren
Zudan
|
|
11 |
|
Darbepoetin alfa |
Approved, Investigational |
Phase 3 |
|
11096-26-7, 209810-58-2 |
|
Synonyms:
Darbepoetin
Darbepoetin alfa,recombinant
|
|
|
12 |
|
Caspofungin |
Approved |
Phase 3 |
|
162808-62-0, 179463-17-3 |
2826718 468682 |
Synonyms:
(4R,5S)-5-((2-aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide
(4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide
[1(R)-hydroxyethyl]-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0(9,13)]heptacosane-2,5,8,14,17,23-hexaone diacetate
1-[(4R,5S)-5-[(2-aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0
162808-62-0
AC1L45LR
AC1LAHR5
AC1MCVUN
AR-1K4318
Cancidas
Cancidas (TM)
Cancidas (TN)
Capsofungin
CASPO
Caspofungin
Caspofungin (INN)
Caspofungin [INN]
Caspofungin acetate
Caspofungin MSD
Caspofungina
|
CHEBI:474180
CHEMBL374999
CHEMBL499808
CID151068
CID2826718
CID468682
D07626
DB00520
HSDB 7476
L-743,872
LS-186994
LS-187303
LS-187635
M991
MK-0991
n-{(2r,6s,9s,11r,12s,14as,15s,20s,23s,25as)-12-[(2-aminoethyl)amino]-20-[(1r)-3-amino-1-hydroxypropyl]-23-[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,15-trihydroxy-6-[(1r)-1-hydroxyethyl]-5,8,14,19,22,25-hexaoxotetracosahydro-1h-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-10,12-dimethyltetradecanamide
N-{(2R,6S,9S,11R,12S,14aS,15S,20S,23S,25aS)-12-[(2-aminoethyl)amino]-20-[(1R)-3-amino-1-hydroxypropyl]-23-[(1S2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,15-trihydroxy-6-[(1R)-1-hydroxyethyl]-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-10,12-dimethyltetradecanamide
nchembio.184-comp7
Pneumocandin B0, 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]- (9CI)
UNII-F0XDI6ZL63
|
|
13 |
|
Thiotepa |
Approved, Investigational |
Phase 2, Phase 3 |
|
52-24-4 |
5453 |
Synonyms:
Girostan
Tepadina
Tespa
Tespamin
thio Tepa
Thiophosphamide
|
Thioplex
thio-Tepa
Thiotepa
Triethylenethiophosphoramide
Tris(1-aziridinyl)phosphine sulfide
|
|
14 |
|
Cladribine |
Approved, Investigational |
Phase 3 |
|
4291-63-8 |
20279 |
Synonyms:
(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
(2R,3S,5R)-5-(6-amino-2-Chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
2 Chlorodeoxyadenosine
24757-90-2
2CdA
2-CdA
2-chloro-2'-Deoxyadenosine
2-Chloro-2'-deoxyadenosine
2-chloro-2'-Deoxy-b-adenosine
2-chloro-2'-Deoxy-beta-adenosine
2-Chloro-2'-deoxy-beta-adenosine
2-chloro-2'-Deoxy-β-adenosine
2-chloro-6-amino-9-(2-Deoxy-b-D-erythro-pentofuranosyl)purine
2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine
2-chloro-6-amino-9-(2-Deoxy-beta-D-erythro-pentofuranosyl)purine
2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine
2-chloro-6-amino-9-(2-deoxy-β-D-erythro-pentofuranosyl)purine
2-chloro-6-amino-9-(2-Deoxy-β-D-erythro-pentofuranosyl)purine
2-chloro-deoxyadenosine
2-chloro-Deoxyadenosine
2-Chlorodeoxyadenosine
2ClAdo
2'-Deoxy-2-chloroadenosine
4291-63-8
AC1L2FXP
AC-7591
Adenosine, 2-chloro-2'-deoxy
BRN 0624220
C10H12ClN5O3.C3H8
CHEBI:567361
CHEMBL1619
Chlorodeoxyadenosine
CID20279
CL9
Cladarabine
Cladaribine
cladribina
Cladribina
cladribine
Cladribine
|
Cladribine (JAN/USAN/INN)
Cladribine [USAN:INN:BAN]
cladribinum
Cladribinum
CldAdo
CPD000058553
D01370
D017338
DB00242
FT-0080707
HMS2052K13
HSDB 7564
Leustat
Leustatin
Leustatin (TN)
Leustatin, 2-chlorodeoxyadenosine, Cladribine
Litak
LS-15109
MLS000028377
MLS000028484
MLS000759397
MLS001077345
MolPort-002-054-532
MolPort-005-935-074
Movectro
Mylinax
NCGC00022567-05
NCGC00164384-01
NSC 105014
NSC 105014-F
NSC-105014
RWJ 26251
RWJ-26251
RWJ-26251-000
S1199_Selleck
SAM001246526
SMR000058553
UNII-47M74X9YT5
ZINC03798064
|
|
15 |
|
Dalteparin |
Approved |
Phase 3 |
|
9005-49-6 |
|
Synonyms:
|
16 |
|
Tinzaparin |
Approved |
Phase 3 |
|
9041-08-1, 9005-49-6 |
25244225 |
Synonyms:
101921-26-0
102785-31-9
102-94-3
104521-37-1
11078-24-3
11129-39-8
12656-11-0
37324-73-5
9041-08-1
9045-22-1
9075-96-1
913079-23-9
91449-79-5
AC1L1ROY
ALFA 87-120
ALFA 87-163
ALFA 87-198
ALFA 87-81
ALFA 88-247
Allocinnamic acid
alpha-Heparin
Ardeparin
Ardeparin sodium
Arteven
Bemiparin
Bemiparin sodium
Certoparin
CID8784
cis-.beta.-Carboxystyrene
cis-Cinnamic acid
Clivarin
Clivarine
CY 216
Cy 222
Dalteparin
Dalteparin sodium
Depo-Heparin
EINECS 232-681-7
Enoxaparin sodium
Eparina
Eparina [DCIT]
Fluxum
FR 860
Fragmin A
Fragmin B
Fragmin IV
Fraxiparin
H 2149
Hed-heparin
Hep Flush Kit in plastic container
heparin
Heparin CY 216
Heparin Lock Flush
Heparin Lock Flush in plastic container
Heparin Lock Flush preservative free
Heparin Lock Flush preservative free in plastic container
Heparin natrium
Heparin sodium
Heparin sodium 1,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 1,000 units in dextrose 5% in plastic container
Heparin sodium 1,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 10,000 units in dextrose 5%
Heparin sodium 10,000 units in dextrose 5% in plastic container
Heparin sodium 10,000 units in sodium chloride 0.45%
Heparin sodium 10,000 units in sodium chloride 0.9%
Heparin sodium 12,500 units in dextrose 5%
Heparin sodium 12,500 units in dextrose 5% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.45% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.9%
Heparin sodium 2,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 2,000 units in dextrose 5% in plastic container
Heparin sodium 2,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 20,000 units and dextrose 5% in plastic container
Heparin sodium 20,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units and dextrose 5% in plastic container
Heparin sodium 25,000 units in dextrose 5%
Heparin sodium 25,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.45% in plastic container
|
Heparin sodium 25,000 units in sodium chloride 0.9%
Heparin sodium 25,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units in dextrose 5% in plastic container
Heparin sodium 5,000 units in sodium chloride 0.45%
Heparin sodium 5,000 units in sodium chloride 0.9%
Heparin sodium 5,000 units in sodium chloride 0.9% in plastic container
Heparin sodium in plastic container
Heparin sodium preservative Free
Heparin sulfate
Heparin, sodium salt
Heparina
Heparina [INN-Spanish]
Heparinate
Heparine
Heparine [INN-French]
Heparinic acid
Heparinum
Heparinum [INN-Latin]
Heparinum natricum
Hepathrom
Hepflush-10
Hep-Lock
Hep-Lock U/P
HSDB 3094
Innohep
Inno-Hep
Isocinnamic acid
Kabi 2165
KB 101
LHN 1
Lioton 1000
Lipo-hepin
Liquaemin
Liquaemin Lock Flush
Liquaemin Sodium
Liquaemin sodium preservative free
Liquemin
Logiparin
Minolteparin sodium
MolPort-003-760-257
Multiparin
Nadroparin
Nadroparine
Novoheparin
NSC174025
Octaparin
OP 386
OP 622
Pabyrin
Panheprin
Parnaparin
Parnaparin sodium
Parvoparin
Pularin
Reviparin
Reviparin sodium
Ro 11
Sandoparin
Sodium acid heparin
Sodium heparin
Sodium heparinate
Subeparin
Sublingula
Thromboliquine
Tinzaparin
Tinzaparin sodium
Tinzaparina
Triofiban
UNII-12M44VTJ7B
UNII-3S182ET3UA
UNII-E47C0NF7LV
UNII-T2410KM04A
UNII-ZZ45AB24CA
Vetren
Vitrum AB
WY 90493RD
|
|
17 |
|
Carboplatin |
Approved |
Phase 2, Phase 3 |
|
41575-94-4 |
10339178 38904 498142 |
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
azanide
Blastocarb
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
Carbopaltin
Carboplat
carboplatin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Carbosin
Carbotec
Cbdca
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
Cyclobutane-1,1-dicarboxylate
cyclobutane-1,1-dicarboxylic acid
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
|
DivK1c_000892
EINECS 255-446-0
Ercar
EU-0100230
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
IUPAC: Azane
JM 8
JM8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
Lopac0_000230
Lopac-C-2538
LS-117689
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
Nealorin
Neocarbo
NINDS_000892
NSC 201345
NSC 241240
NSC201345
NSC241240
NSC-241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
platinum(2+)
Platinum(II), (1, 1-cyclobutanedicar
Platinum, {diammine[1,1-cyclobut
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Ribocarbo
S1215_Selleck
SPBio_000716
Spectrum_001529
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
UNII-BG3F62OND5
|
|
18 |
|
Dextromethorphan |
Approved |
Phase 3 |
|
125-71-3 |
5360696 5362449 |
Synonyms:
( )-3-Methoxy-N-methylmorphinon
( )-cis-1,3,4,9,10,10a-Hexahydro-6-methoxy-11-methyl-2H-10,4alpha-iminoethanophenanthren
(-)-3-Methoxy-N-methylmorphinan
(+)-3-Methoxy-17-methylmorphinan
(+)-dextromethorphan
(9alpha,13alpha,14alpha)-17-methyl-3-(methyloxy)morphinan
125-69-9 (hydrobromide)
125-70-2
125-71-3
18046-32-7
18609-21-7 (hydrochloride)
32062-10-5
3-Methoxy-17-methyl-9alpha,13alpha,14alpha-morphinan
3-Methoxy-17-methylmorphinan
4-21-00-01367 (Beilstein Handbook Reference)
6700-34-1 (hydrobromide, mono-hydrate)
9alpha,13alpha,14alpha-Morphinan, 3-methoxy-17-methyl- (8CI)
AC-13098
AC1L1EYT
Albutussin
Antussan
BA 2666
Balminil DM
Balminil DM Children
Bayer select flu relief
Bayer select head & chest cold
Bayer select night time cold
Benylin Adult Formula Cough Suppressant
Benylin DM
Benylin DM 12 Hour
Benylin DM for Children
Benylin DM for Children 12 Hour
Benylin Pediatric Cough Suppressant
BPBio1_000503
BRD-K33211335-337-03-7
BRN 0088549
BSPBio_000457
C06947
Calmylin #1
Canfodion
Cerose-DM
CHEBI:128891
CHEBI:4470
CHEBI:580686
CHEMBL22207
CHEMBL52440
Chloraseptic DM
CID3008
CID5360696
CID5362449
Contac day & night cold/flu day caplets
Contac jr. non-drowsy formula
Contac nighttime cold medicine
Contac severe cold formula maximum strength
Contac severe cold formula non-drowsy
Coricidin syrup
Cosylan
Cough-X
Creo-Terpin
D03742
DB00514
DEA No. 9210
Delsym
Delsym Cough Formula
delta-Methorphan
Delta-Methorphan
Demorphan
Demorphan hydrobromide
Demorphan Hydrobromide
Demorphine
Destrometerfano
Destrometerfano [Dcit]
Destrometerfano [DCIT]
Dex
Dextromethorfan
Dextromethorfan [Czech]
dextromethorphan
Dextromethorphan
Dextromethorphan (USP)
Dextromethorphan [USP:INN:BAN]
Dextromethorphan bromhydrate
Dextromethorphan Bromhydrate
Dextromethorphan bromide
Dextromethorphan Bromide
Dextromethorphan hydrobromide
Dextromethorphan hydrobromide monohydrate
Dextromethorphan hydrobromide oros tablets
Dextromethorphan hydrobromide, (+-)-isomer
Dextromethorphan hydrobromide, monohydrate
Dextromethorphan hydrochloride
Dextromethorphan, (+-)-isomer
Dextromethorphane
Dextrométhorphane
Dextromethorphane [INN-French]
Dextromethorphanum
Dextromethorphanum [INN-Latin]
Dextrometorfano
Dextrometorfano [INN-Spanish]
Dextrometorphan
Dextromorphan
Dexyromethorphan
Diabe-Tuss DM Syrup
Dimacol
Dimetapp DM
DM
d-Methorphan
|
D-methorphan
D-Methorphan
D-Methorphan hydrobromide
D-Methorphan Hydrobromide
Dormetan
Dormethan
Drixoral cough
Drixoral cough & congestion
Drixoral cough & sore throat
DXM
EINECS 204-751-7
EINECS 204-752-2
Endotussin-NN
Endotussin-NN pediatric
Hihustan M.
HMS2090C08
Hold
Hold DM
HSDB 3056
Hydrobromide, dextromethorphan
Hydrochloride, dextromethorphan
Koffex DM
Levomethorphan
Levomethorphan [Ban:Dcf:Inn]
Levomethorphan [BAN:DCF:INN]
Levomethorphan [INN:BAN:DCF]
Levomethorphane
Levomethorphane [INN-French]
Levomethorphanum
Levomethorphanum [INN-Latin]
Levometorfano
Levometorfano [INN-Spanish]
l-Methorphan
L-Methorphan
Lopac0_000337
Lopac-D-2531
LS-91837
LS-91838
Medicon
Methorate
Methorate Hydrobromide
Methorphan
Metrorat
MLS000758303
MolPort-003-940-943
MolPort-004-285-957
Morphinan, 3-methoxy-17-methyl-, (9-alpha,13-alpha,14-alpha)- (9CI)
Naldecon-DX
NCGC00015333-01
NCGC00015333-02
NCGC00015333-04
NCGC00162126-01
Novahistex DM
Novahistine DM
Ornex severe cold formula
Orthoxicol
PediaCare 1
PediaCare cough-cold formula
Pertussin CS Children's Strength
Pertussin DM Extra Strength
Prestwick_686
Prestwick0_000359
Prestwick1_000359
Prestwick2_000359
Prestwick3_000359
Racemethorphan
RACEMETHORPHAN
Robitussin CF
Robitussin cold & cough
Robitussin cough calmers
Robitussin DM
Robitussin maximum strength cough
Robitussin Maximum Strength Cough Suppressant
Robitussin Pediatric
Robitussin pediatric cough
Robitussin pediatric cough & cold
Robitussin Pediatric Cough Suppressant
Robitussin pediatric night relief
Romilar
Rondec DM
Ru-tuss expectorant
SPBio_002378
St. joseph cough syrup
Sucrets 4 Hour Cough Suppressant
Sudafed cough syrup
Triaminic
Triaminic DM Long Lasting for Children
Trind-DM
Trocal
Tusilan
Tussade
Tussar DM
Tussi-organidin
Tussi-organidin DM NR
Tussi-organidin DM-S NR
Tylenol cold and flu multi-symptom
Tylenol cold and flu no drowsiness
Tylenol cold no drowsiness
Tylenol cough + decongestant liquid
Tylenol cough liquid
Tylenol flu no drowsiness gelcaps
UNII-7355X3ROTS
Vicks 44 Cough Relief
viro-Med
δ-methorphan
|
|
19 |
|
Fentanyl |
Approved, Illicit, Investigational, Vet_approved |
Phase 3 |
|
437-38-7 |
3345 |
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-phenethyl-4-N-propionylanilinopiperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
Cephalon brand OF fentanyl buccal oravescent
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
fentanyl
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl [INN:BAN]
Fentanyl CII
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
Fentanyl-50
|
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
Fentora
HSDB 3329
IONSYS
Janssen pharmaceutica brand OF fentanyl
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
Nasalfent
NCGC00168252-01
N-phenethyl-4-(N-propionylanilino)piperidine
N-Phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Transmucosal oral fentanyl citrate
UNII-UF599785JZ
|
|
20 |
|
Iron |
Approved, Experimental |
Phase 3 |
|
15438-31-0, 7439-89-6 |
27284 23925 |
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
Ancor B
Ancor en 80/150
armco Iron
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
ATW 230
ATW 432
C00023
C3518_SIAL
C3518_SIGMA
Carbonyl iron
CCRIS 1580
CHEBI:18248
CID23925
Copy Powder CS 105-175
D007501
DB01592
Diseases (animal), iron overload
Diseases, iron overload
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Ed-In-Sol
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
Eisen
Electrolytic iron
F 60 (metal)
Fe
FE
FE (II) ion
Fe(2+)
Fe(II)
Fe1+
Fe2+
Fe-40
|
fer
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrous ion
ferrous iron
Ferrousal
Ferrovac e
Ferrovac E
Ferrum
Ferrum metallicum
FT 3 (element)
GS 6
Hematite
Hemocyte
HF 2 (element)
hierro
Hierro
HL (iron)
Hoeganaes ATW 230
Hoeganaes EH
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Infed
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron ion(2+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(2+)
Iron(2+) ion
Iron(II) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, ion (Fe2+)
Iron, reduced
Limonite
LOHA
LS-3196
Magnetite
Malleable iron
Metopirone
Metyrapone
MolPort-003-925-001
NC 100
PZh1M1
PZh-1M3
PZh-2
PZh2M
PZH2m
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
PZHO
Reduced iron
Remko
Siderol
Suy-b 2
SUY-B 2
Taconite
UNII-E1UOL152H7
Venofer
Vitedyn-Slo
Wrought iron
Yieronia
|
|
21 |
|
Amphotericin B |
Approved, Investigational |
Phase 3 |
|
1397-89-3 |
5280965 14956 |
Synonyms:
12633-72-6
1397-89-3
30782-62-8
5-18-10-00525 (Beilstein Handbook Reference)
54482-28-9
8055-20-7
AB00513832
Abelcet
Abelecet
ABLC
AC1L1CN2
AC1L24V6
AC1L70KF
AC1L73U6
AC1NQXTD
AC1NTQ32
AC1NUQG4
AC1NY9JC
AC1O7GCZ
AC1O8FQV
AC1O8PFK
AI3-26528
Ambap1397-89-3
Ambisome
AmBisome (TN)
Amfotericina b
Amfotericina B
Amfotericina B [INN-Spanish]
amophotericin B
AMPH-b
AMPH-B
Amphocil
Amphocin
Amphomoronal
Ampho-Moronal
Amphortericin b
Amphortericin B
Amphotec
Amphotec (TN)
Amphotericin
Amphotericin .BETA.
amphotericin b
Amphotericin B
Amphotericin B (JP15/USP/INN)
Amphotericin B [USAN:INN:JAN]
Amphotericin b cholesterol dispersion
Amphotericin B Cholesterol Dispersion
Amphotericin b colloidal dispersion
Amphotericin B Colloidal Dispersion
amphotericin B liposomal
Amphotericin B, Lipid-based
Amphotericin B, Streptomyces sp.
Amphotericin-B
Amphotericine b
Amphotericine B
Amphotéricine B
Amphotericine B [INN-French]
Amphotericinum
Amphotericinum b
Amphotericinum B
Amphotericinum B [INN-Latin]
Amphotherizin
Amphotherizin [German]
Amphozone
BIDD:GT0351
BPBio1_000374
BRN 0078342
BSPBio_000340
C06573
C47H73NO17
CCRIS 5963
CHEBI:2682
CHEMBL1200646
CHEMBL267345
|
CID10533925
CID10629638
CID10677275
CID14956
CID1972
CID352546
CID354192
CID5280965
CID5386092
CID5458486
CID5771695
CID6604295
CID6708817
CID6713692
CID9919339
D00203
DB00681
DivK1c_007045
EINECS 215-742-2
Fungilin
Fungisome
Fungisone
Fungizone
Fungizone (TN)
Halizon
HMS1569A22
HSDB 3008
HSDB 3008 IAB
I06-0257
KBio1_001989
KBio2_000551
KBio2_003119
KBio2_005687
KBioGR_002298
KBioSS_000551
Liposomal amphotericin b
Liposomal amphotericin B
Liposomal Amphotericin B
LMPK06000002
LNS-AmB
LS-187721
LS-93
MLS002702966
MolPort-006-392-260
Mysteclin-F
NCGC00014913
NCGC00090808-01
NCGC00098014-01
NCGC00179595-01
NCI527017
NCI60_004288
NCIStruc1_001042
NCIStruc2_000920
NKTR-024
NS 718
NSC 527017
NSC527017
NSC-527017
Prestwick_721
Prestwick0_000410
Prestwick1_000410
Prestwick2_000410
Prestwick3_000410
SinuNase
SMP1_000302
SMR001566780
SPBio_000715
SPBio_002279
SpecPlus_000949
Spectrum_000111
Spectrum2_000818
Spectrum4_001779
ST50999656
UNII-7XU7A7DROE
|
|
22 |
|
Ginseng |
Approved, Investigational, Nutraceutical |
Phase 3 |
|
50647-08-0 |
|
Synonyms:
Aralia ginseng root
Asian ginseng root
Chinese ginseng root
Ginseng (panax ginseng)
Ginseng extract
Ginseng, asian
Hong shen root
Insam root
Korean ginseng
Korean ginseng root
Ninjin root
|
Panax ginseng
Panax ginseng root
Panax ginseng root extract
Panax schinseng root
Panax verus root
Red ginseng
Ren seng root
Ren shen
Ren shen root
True ginseng root
|
|
23 |
|
Pancreatic Polypeptide |
Investigational |
Phase 3 |
|
59763-91-6 |
|
24 |
|
Anesthetics, Dissociative |
|
Phase 3 |
|
|
|
25 |
|
Anti-Bacterial Agents |
|
Phase 3 |
|
|
|
26 |
|
Anti-Infective Agents |
|
Phase 3 |
|
|
|
27 |
|
Antifungal Agents |
|
Phase 3 |
|
|
|
28 |
|
Dermatologic Agents |
|
Phase 3 |
|
|
|
29 |
|
Analgesics |
|
Phase 3 |
|
|
|
30 |
|
Etoposide phosphate |
|
Phase 2, Phase 3 |
|
|
|
31 |
|
Cola |
|
Phase 3 |
|
|
|
32 |
|
Liver Extracts |
|
Phase 3 |
|
|
|
33 |
|
Gastrointestinal Agents |
|
Phase 3 |
|
|
|
34 |
|
Antiemetics |
|
Phase 3 |
|
|
|
35 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
36 |
|
Analgesics, Opioid |
|
Phase 3 |
|
|
|
37 |
|
Psychotropic Drugs |
|
Phase 3 |
|
|
|
38 |
|
Anti-Anxiety Agents |
|
Phase 3 |
|
|
|
39 |
|
Antipsychotic Agents |
|
Phase 3 |
|
|
|
40 |
|
Hematinics |
|
Phase 3 |
|
|
|
41 |
|
Epoetin alfa |
|
Phase 3 |
|
113427-24-0 |
|
42 |
|
Fibrinolytic Agents |
|
Phase 3 |
|
|
|
43 |
|
Antiprotozoal Agents |
|
Phase 3 |
|
|
|
44 |
|
Antiparasitic Agents |
|
Phase 3 |
|
|
|
45 |
|
Heparin, Low-Molecular-Weight |
|
Phase 3 |
|
|
|
46 |
|
Excitatory Amino Acid Antagonists |
|
Phase 3 |
|
|
|
47 |
|
Narcotics |
|
Phase 3 |
|
|
|
48 |
|
Anesthetics |
|
Phase 3 |
|
|
|
49 |
|
Anesthetics, General |
|
Phase 3 |
|
|
|
50 |
|
Anesthetics, Intravenous |
|
Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 207)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB |
Unknown status |
NCT00020865 |
Phase 3 |
cefepime hydrochloride;levofloxacin |
2 |
A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients |
Unknown status |
NCT01316744 |
Phase 3 |
ketamine hydrochloride |
3 |
A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy |
Completed |
NCT00070382 |
Phase 3 |
darbepoetin alfa;epoetin alfa |
4 |
A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial |
Completed |
NCT01231412 |
Phase 3 |
Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus |
5 |
Daily Versus Weekly Administration of 2-Chlorodeoxyadenosine (CDA) in Patients With Hairy Cell Leukemia |
Completed |
NCT00003746 |
Phase 3 |
2-chlorodeoxyadenosine (CDA) daily;2-chlorodeoxyadenosine weekly |
6 |
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer |
Completed |
NCT00006348 |
Phase 3 |
ondansetron |
7 |
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters |
Completed |
NCT00006083 |
Phase 3 |
Fragmin |
8 |
Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia |
Completed |
NCT00003816 |
Phase 2, Phase 3 |
busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa |
9 |
A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients |
Completed |
NCT00003687 |
Phase 3 |
dextromethorphan hydrobromide;morphine sulfate |
10 |
A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia |
Completed |
NCT00661999 |
Phase 3 |
sodium ferric gluconate complex in sucrose |
11 |
Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) |
Completed |
NCT00750009 |
Phase 3 |
|
12 |
A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials |
Completed |
NCT00003938 |
Phase 3 |
liposomal amphotericin B |
13 |
A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia |
Completed |
NCT00008359 |
Phase 3 |
caspofungin acetate;liposomal amphotericin B |
14 |
The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study |
Completed |
NCT00719563 |
Phase 3 |
American ginseng |
15 |
Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. |
Completed |
NCT00666211 |
Phase 3 |
|
16 |
A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain |
Completed |
NCT00538850 |
Phase 3 |
Fentanyl sublingual spray;Placebo |
17 |
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma |
Unknown status |
NCT02819583 |
Phase 1, Phase 2 |
|
18 |
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma |
Unknown status |
NCT02851589 |
Phase 1, Phase 2 |
|
19 |
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Relapsed or Refractory Leukemia and Lymphoma |
Unknown status |
NCT02892695 |
Phase 1, Phase 2 |
|
20 |
Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma |
Unknown status |
NCT02742727 |
Phase 1, Phase 2 |
|
21 |
Pilot Study of Redirected Autologous T Cells Transduced to Express A CD20-Specific Chimeric Immunoreceptor in Patient With Chemotherapy Resistant or Refractory CD20+ Leukemia and Lymphoma |
Unknown status |
NCT01735604 |
Phase 1, Phase 2 |
|
22 |
A Pilot Study to Assess the Feasibility of Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Third-party Mesenchymal Stem Cells After Myeloablative or Nonmyeloablative Conditioning in Patients With Hematological Malignancies |
Unknown status |
NCT01092026 |
Phase 1, Phase 2 |
|
23 |
Allogeneic Hematopoietic Stem Cell Transplantation With Nonmyeloablative Conditioning for Patients With Chronic Lymphocytic Leukemia - A Multi-center Trial |
Completed |
NCT00060424 |
Phase 2 |
Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil |
24 |
Phase II Trial of Combined Immunochemotherapy With Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients With Previously Treated or Untreated T-Prolymphocytic Leukemia |
Completed |
NCT01186640 |
Phase 2 |
Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab;Alemtuzumab |
25 |
Consolidation With Campath-1H After FMC Induction in Patients With T-cell Chronic Lymphocytic Leukemia |
Completed |
NCT00278213 |
Phase 2 |
cyclophosphamide;fludarabine phosphate;mitoxantrone hydrochloride |
26 |
A Phase II Trial of Post-Transplant Cyclophosphamide and Sirolimus for Graft-versus-host Disease (GVHD) Prophylaxis Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation |
Completed |
NCT01244906 |
Phase 2 |
|
27 |
A Multicenter, Open-label, Single Arm Study of Weekly Alvocidib in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) Arising From CLL |
Completed |
NCT00464633 |
Phase 2 |
alvocidib |
28 |
A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Nonmyeloablative Allogeneic Stem Cell Transplantation for Patients With Relapsed or Refractory Lymphoma - A Multi-center Trial |
Completed |
NCT00005803 |
Phase 1, Phase 2 |
Carmustine;Cyclophosphamide;Cyclosporine;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil |
29 |
Phase 1b/2 Study of Dinaciclib (SCH 727965) and Ofatumumab in Relapsed and Refractory CLL/SLL/B-PLL |
Completed |
NCT01515176 |
Phase 1, Phase 2 |
Dinaciclib |
30 |
Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia |
Completed |
NCT01008462 |
Phase 2 |
Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus |
31 |
A Phase II Study to Assess Immunosuppression With Sirolimus Combined With Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD After Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation- A Multi-Center Trial |
Completed |
NCT01251575 |
Phase 2 |
Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus |
32 |
Minimal Ablation and Cellular Immune Therapy of Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Low-Grade Non-Hodgkin's Lymphoma, and Mantle Cell Lymphoma With Allogeneic Donor Stem Cells |
Completed |
NCT00006252 |
Phase 2 |
fludarabine phosphate;Cyclophosphamide;G-CSF |
33 |
A Phase I Phase II Two-Step Study of the Oral Gold Compound Auranofin in Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)/ Prolymphocytic Lymphoma (PLL) |
Completed |
NCT01419691 |
Phase 2 |
auranofin |
34 |
Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies |
Completed |
NCT01093586 |
Phase 2 |
busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil |
35 |
Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial |
Completed |
NCT00104858 |
Phase 2 |
Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil |
36 |
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation |
Completed |
NCT00053196 |
Phase 2 |
busulfan;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus;allopurinol |
37 |
Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy |
Completed |
NCT00255749 |
Phase 2 |
|
38 |
Phase I/II Study of Subcutaneously Administered Veltuzumab (hA20) in Patients With CD20+ Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia |
Completed |
NCT00546793 |
Phase 1, Phase 2 |
|
39 |
A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) |
Completed |
NCT00110045 |
Phase 2 |
caspofungin acetate |
40 |
Trial of Immune Reconstitution With Activated T-Cells in Patients With Chronic Lymphocytic Leukemia (CLL) |
Completed |
NCT02530515 |
Phase 2 |
|
41 |
A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil |
Completed |
NCT00089011 |
Phase 2 |
fludarabine phosphate;mycophenolate mofetil;tacrolimus |
42 |
Donor Statin Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Hematopoietic Cell Transplantation |
Completed |
NCT01527045 |
Phase 2 |
Atorvastatin Calcium;Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil |
43 |
Transplantation of Unrelated Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen |
Completed |
NCT00309842 |
Phase 2 |
cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil |
44 |
An Open-label, Phase 1b/2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, and Ofatumumab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Prolymphocytic Leukemia |
Completed |
NCT01217749 |
Phase 1, Phase 2 |
PCI-32765;ofatumumab |
45 |
Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) in Newly Diagnosed and Relapsed Indolent Lymphoproliferative Malignancies |
Completed |
NCT00005626 |
Phase 2 |
Irinotecan |
46 |
A Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Patients With Richter's Transformation, Prolymphocytic Leukemia or Refractory/Relapsed B-Cell Chronic Lymphocytic Leukemia |
Completed |
NCT00452374 |
Phase 1, Phase 2 |
Cytarabine;Fludarabine;Oxaliplatin;Rituximab |
47 |
A Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation, Prolymphocytic Leukemia, Aggressive, Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia |
Completed |
NCT00472849 |
Phase 1, Phase 2 |
Oxaliplatin;Fludarabine;Cytarabine;Rituximab;Pegfilgrastim |
48 |
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825) |
Completed |
NCT00364286 |
Phase 2 |
Dasatinib (BMS-354825) |
49 |
Phase II Multicenter Trial Of Pentostatin and Rituximab In Patients With Previously Treated and Untreated Low Grade B-Cell Non-Hodgkin's Lymphoma (NHL) Including Chronic Lymphocytic Leukemia (CLL) |
Completed |
NCT00026351 |
Phase 2 |
pentostatin |
50 |
OUTPATIENT SUBCUTANEOUS IL-2 AND ALPHA INTERFERON IN THE MANAGEMENT OF METASTATIC CANCER |
Completed |
NCT00002504 |
Phase 2 |
|
|